Clinical Trials

854 enrolled

Hematologic Diseases, Multiple Myeloma

NCT06015880 2026-04-16

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06649812 2026-04-16

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2 Recruiting

120 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07095452 2026-04-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Multiple Myeloma

NCT02420860 2026-04-15

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

113 enrolled

Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

67 enrolled

Multiple Myeloma

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05623020 2026-04-15

MagnetisMM-6

1,116 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Multiple Myeloma

NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase 1 Completed

18 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02203643 2026-04-14

FORTE

Phase 2 Completed

477 enrolled

Multiple Myeloma

NCT06182774 2026-04-14

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

570 enrolled

Multiple Myeloma

NCT00843882 2026-04-13

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01711554 2026-04-13

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

27 enrolled

CNS

Neuroblastoma

NCT02160015 2026-04-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03269669 2026-04-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03901963 2026-04-13

AURIGA

200 enrolled 12 charts

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT04301076 2026-04-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04623541 2026-04-13

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04722146 2026-04-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05438043 2026-04-13

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05552222 2026-04-13

MajesTEC-7

1,590 enrolled

Multiple Myeloma

NCT06149286 2026-04-13

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06169215 2026-04-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

70 enrolled

Multiple Myeloma

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06577025 2026-04-13

aMMbition

43 enrolled

Multiple Myeloma

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Multiple Myeloma

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01054196 2026-04-08

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

52 enrolled 15 charts

Multiple Myeloma

NCT01241734 2026-04-08

RICER

Phase 1/2 Completed

18 enrolled 15 charts

Lymphoma, Large B-Cell, Diffuse

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT04542824 2026-04-08

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-04-08

EPCORE DLBCL-3

111 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03993912 2026-04-07

IFM2017_03

294 enrolled

Multiple Myeloma

NCT07030699 2026-04-07

ECLAT

Phase 2 Withdrawn

Lymphoma

NCT00430365 2026-04-06

IFM2005-02

Phase 3 Completed

614 enrolled

Neoplasms, Plasma Cell

NCT01191060 2026-04-06

IFM/DFCI2009

Phase 3 Completed

700 enrolled

Disease Progression, Neoplasms, Plasma Cell

NCT01723839 2026-04-03

FCR

Phase 2 Completed

21 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03937635 2026-04-03

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

288 enrolled

Smoldering Multiple Myeloma

NCT04566328 2026-04-03

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

1,450 enrolled

Multiple Myeloma

NCT05583617 2026-04-03

PLYCOM

Phase 1/2 Recruiting

200 enrolled

Multiple Myeloma

NCT06084936 2026-04-02

GLOBRYTE

182 enrolled

Lymphoma

NCT06918002 2026-04-02

ElLen

824 enrolled